Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment

Neurosurgery

Volumn 45, Issue 6, 1999, Pages 1279-1291

  Fortin, David ^a,d   Cairncross, Gregory J ^b,c   Hammond, Robert R ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LONDON REGIONAL CANCER PROGRAM   (Canada)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Chemotherapy; Grading; Histology; Oligodendroglioma; Radiotherapy; Resection extent

Indexed keywords

ANTINEOPLASTIC AGENT; LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ANOREXIA; AUTONOMIC NEUROPATHY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; DATA ANALYSIS; FATIGUE; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; OLIGODENDROGLIOMA; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVIEW;

EID: 0032786118     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199912000-00001     Document Type: Review

References (120)

1. Allison RR, Schulsinger A, Vongtama V, Barry T, Shin KH: Radiation and chemotherapy improve outcome in oligodendroglioma. Int J Radiat Oncol Biol Phys 37:399-403, 1997.
2. Alvord EC Jr: Is necrosis helpful in the grading of gliomas? Editorial opinion. J Neuropathol Exp Neurol 51:127-132, 1992.
3. Alvord EC Jr, Shaw CM: Grading brain tumors other than astrocytomas. Neurosurg Clin N Am 5:43-55, 1994.
4. Apuzzo MLJ: Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 41:1038, 1997 (comment).
5. Archibald YM, Lunn D, Ruttan LA, Macdonald DR, Del Maestro RF, Barr HW, Pexman JH, Fisher BJ, Gaspar LE, Cairncross JG: Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg 80:247-253, 1994.
6. Behar T, McMorris FA, Novotny EA, Barker JL, Dubois-Dalcq M: Growth and differentiation properties of O-2A progenitors purified from rat cerebral hemispheres. J Neurosci Res 21:168-180, 1988.
7. Berger MS: Role of surgery in diagnosis and management, in Apuzzo MLJ (ed): Benign Cerebral Glioma. Park Ridge, AANS, 1995, pp 293-307.
8. Berger MS, Rostomily RC: Low grade gliomas: Functional mapping resection strategies, extent of resection, and outcome. J Neurooncol 34:85-101, 1997.
9. Berger MS, Deliganis AV, Dobbins J, Keles GE: The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74:1784-1791, 1994.
10. Boiardi A, Silvani A, Pozzi A, Farinotti M, Fariselli L, Broggi G, Salmaggi A: Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy. J Neurooncol 34:179-185, 1997.
11. Brada M, Ross G: Radiation therapy in the management of malignant gliomas. Baillieres Clin Neurol 5:319-343, 1996.
12. Brown M, Cairncross JG, Vick NA, Macdonald DR, Friedman HS, Dropcho EJ, Schold SC Jr: Differential response of recurrent oligodendrogliomas versus astrocytomas to intravenous melphalan. Neurology 40[Suppl 1]:397-398, 1990.
13. Bruner JM: Oligodendroglioma: Diagnosis and prognosis. Semin Diagn Pathol 4:251-261, 1987.
14. Bruner JM: Neuropathology of malignant gliomas. Semin Oncol 21:126-138, 1994.
15. Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold SC Jr, Bullard DE: Clinicopathologic correlations in the oligodendroglioma. Cancer 59:1345-1352, 1987.
16. Cairncross JG, Eisenhauer EA: Response and control: Lessons from oligodendroglioma. J Clin Oncol 13:2475-2476, 1995.
17. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23:360-364, 1988.
18. Cairncross J, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr, Wainman N, Eisenhauer E, for the National Cancer Institute of Canada Clinical Trial Group: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12:2013-2021, 1994.
19. Cairncross JG, Macdonald DR, Ramsay DA: Aggressive oligodendroglioma: A chemosensitive tumor. Neurosurgery 31:78-82, 1992.
20. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998.
21. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A: Cerebral oligodendroglioma: Prognostic factors and life history. Neurosurgery 35:1018-1035, 1994.
22. Chin KW, Young AB, Maruyama Y: Survival and response of malignant gliomas to radiotherapy with or without BCNU or methyl-CCNU at the University of Kentucky Medical Center. Cancer Treat Rep 65:45-51, 1981.
23. Ciric I, Vick NA, Mikhael MA, Cozzens J, Eller T, Walsh A: Aggressive surgery for malignant supratentorial gliomas. Clin Neurosurg 36:375-383, 1990.
24. Coons SW, Johnson PC: Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labelling index. J Neuropathol Exp Neurol 52:609-618, 1993.
25. Coons SW, Johnson PC, Pearl DK: The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 41:878-885, 1997.
26. Coons SW, Johnson PC, Pearl DK, Olafsen AG: Prognostic significance of flow cytometry deoxyribonucleic acid analysis of human oligodendrogliomas. Neurosurgery 34:680-687, 1994.
27. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381-1393, 1997.
28. Crossen JR, Garwood D, Galstein E, Neuwelt EA: Neurobehavioral sequelae of cranial irradiation in adults: A review of radiation-induced encephalopathy. J Clin Oncol 12:627-642, 1994.
29. Daumas-Duport C: Histological grading of gliomas. Curr Opin Neurol Neurosurg 5:924-931, 1992.
30. Daumas-Duport C: The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 41:885, 1997 (comment).
31. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P: Grading of astrocytomas: A simple and reproducible method. Cancer 64: 2152-2165, 1988.
32. Daumas-Duport C, Tucker M-L, Kolles H, Cervera P, Beuvon F, Varlet P, Udo N, Koziak M, Chodkiewicz JP: Oligodendrogliomas: Part II - A new grading system based on morphological and imaging criteria. J Neurooncol 34:61-78, 1997.
33. Daumas-Duport C, Varlet P, Tucker M-L, Beuvon F, Cervera P, Chodkiewicz J-P: Oligodendrogliomas: Part 1 - Patterns of growth, histological diagnosis, clinical and imaging correlations: A study of 153 cases. J Neurooncol 34:37-59, 1997.
34. de la Monte SM: Uniform lineage of oligodendrogliomas. Am J Pathol 135:529-540, 1989.
35. 11C-L-methylmethionine. Neurosurgery 40:276-288, 1997.
36. Devaux BC, O'Fallon JR, Kelly PJ: Resection, biopsy, and survival in malignant glial neoplasms: A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78:767-775, 1993.
37. Donahue B, Scott CB, Nelson JS, Rotman M, Murray KJ, Nelson DF, Banker FL, Earle JD, Fischdach JA, Asbell SO, Gaspar LE, Markoe AM, Curran W: Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: A report of Radiation Therapy Oncology Group 83-02. Int J Radiat Oncol Biol Phys 38:911-914, 1997.
38. Earnest F III, Kernohan JW, Craig WM: Oligodendrogliomas: A review of two hundred cases. Arch Neurol Psychiatr 63:964-976, 1950.
39. Escalone ZJ: Astrocytes in brain tumours: Differentiation or trapping? Histol Histopathol 9:325-332, 1994.
40. Fulton D, Urtasun R, Forsyth P: Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 27:149-155, 1996.
41. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS: The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 30:567-573, 1994.
42. Garrett MJ, Hugues HJ, Freedman LS: A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma. Clin Oncol 4:71-76, 1978.
43. Glantz MJ, Burger PC, Herndon JE II, Friedman AH, Cairncross JG, Vick NA: Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology 41:1741-1744, 1991.
44. Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B: The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 76:741-745, 1992.
45. Gutin PH: Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 41:1037-1038, 1997 (comment).
46. Halperin EC, Gaspar L, Imperato J, Salter M, Herndon J II, Dowling S: An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors: The CNS cancer consortium. Am J Clin Oncol 16:277-283, 1993.
47. Heegaard S, Sommer HM, Broholm H, Broendstrup O: Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 76:1809-1813, 1995.
48. Hochberg FH, Slotnick B: Neuropsychologic impairment in astrocytoma survivors. Neurology 30:172-177, 1980.
49. Jubelirer SJ, Rubin M, Shim C: An analysis of 38 cases of low-grade cerebral astrocytoma in adults. W V Med J 89:102-105, 1993.
50. Karim ABMF, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M, Jager JJ, Fabrini MG, van Alphen AM, Hamers HP, Gaspar L, Noordman E, Pierart M, van Glabbeke M: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 36:549-556, 1996.
51. Kashima T, Vinters HV, Campagnoni AT: Unexpected expression of intermediate filament protein genes in human oligodendroglioma cell lines. J Neuropathol Exp Neurol 54:23-31, 1995.
52. Kernohan JW, Maybon RF, Svien HJ, Adson AW: A simplified classification of the gliomas. Proc Staff Meet Mayo Clin 24:71-75, 1949.
53. Kim L, Hochberg FH, Thornton AF, Harsh GR IV, Patel H, Finkelstein D, Louis DN: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 85:602-607, 1996.
54. Kirby S, Macdonald D, Fisher B, Gaspar L, Cairncross G: Preradiation chemotherapy for malignant glioma in adults. Can J Neurol Sci 23:123-127, 1996.
55. Kleihues P, Burger PC, Scheithauer BW: Hystological typing of tumors of the central nervous system, in International Histological Classification of Tumours. Geneva, World Health Organization, 1995.
56. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC: Histopathology, classification, and grading of gliomas. Glia 15:211-221, 1995.
57. Knisely JPS, Haffty BG, Christopher SR: Early vs. delayed radiotherapy in a small cohort of patients with supratentorial low grade glioma. J Neurooncol 34:23-29, 1997.
58. Kramer S: The hazards of therapeutic irradiation of the central nervous system. Clin Neurosurg 15:301-318, 1968.
59. Kreth FW, Warne PC, Sheremet R, Ostertag CB: Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of GBM. J Neurosurg 78:762-766, 1993.
60. Kros JM, de Jong AA, van der Kwast TH: Ultrastructural characterization of transitional cells in oligodendrogliomas. J Neuropathol Exp Neurol 51:186-193, 1992.
61. Kros JM, Hop WC, Godschalk JJ, Krishnadath KK: Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 78:1107-1113, 1996.
62. Kros JM, Pieterman H, van Eden CG, Avezaat CJ: Oligodendroglioma: The Rotterdam-Dijkzigt experience. Neurosurgery 34: 959-966, 1994.
63. Kros JM, Schouten WCD, Janssen PJA, van der Kwast TH: Proliferation of gemistocytic cells and glial fibrillary acidic protein (GFAP)-positive oligodendroglial cells in gliomas: A MIB-1/ GFAP double labeling study. Acta Neuropathol (Berl) 91:99-103, 1996.
64. Kros JM, Troost D, Van Eden CG, van der Werf JM, Uylings HBM: Oligodendroglioma: A comparison of two grading systems. Cancer 61:2251-2259, 1988.
65. Kros JM, Van Eden CG, Stefanko SZ, Waayer-Van Batenburg M, van der Kwast TH: Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas. Cancer 66:1204-1212, 1990.
66. Kros JM, Van Eden CG, Vissers CJ, Mulder AH, van der Kwast TH: Prognostic relevance of DNA flow cytometry in oligodendroglioma. Cancer 69:1791-1798, 1992.
67. Krouwer HG, van Duinen SG, Kamphorst W, van der Valk P, Algra A: Oligoastrocytomas: A clinicopathological study of 52 cases. J Neurooncol 33:223-238, 1997.
68. Kyritsis AP, Yung WK, Bruner J, Gleason MJ, Levin VA: The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 32:365-371, 1993.
69. Laws ER Jr, Taylor WF, Clifton MB, Okazaki H: Neurosurgical management of low-grade astrocytoma of the cerebral hemisphere. J Neurosurg 61:665-673, 1984.
70. Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, Macdonald D, Cairncross G: Supratentorial low-grade glioma in adults: An analysis of prognostic factors and timing of radiation. J Clin Oncol 15:1294-1301, 1997.
71. Levin VA: Controversies in the treatment of low-grade astrocytomas and oligodendrogliomas. Curr Opin Oncol 8:175-177, 1996.
72. Levin VA, Edwards MS, Wright DC, Seager ML, Pischer-Schimberg T, Townsend JJ, Wilson CB: Modified procarbazine, CCNU and vincristine (PCV-3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64:237-244, 1980.
73. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18:321-324, 1990.
74. Linskey ME: Glial ontogeny and glial neoplasia: The search for closure. J Neurooncol 34:5-22, 1997.
75. Linskey ME, Gilbert MR: Glial differentiation: A review with implications for new directions in neuro-oncology. Neurosurgery 36:1-22, 1995.
76. Loiseau H, Dartigues JF, Cohadon F: Low-grade astrocytomas: Prognosis factors and elements of management. Surg Neurol 44:224-227, 1995.
77. Lote U, Egeland T, Hager B, Stenwig B, Skullerud K, Berg-Johnsen J, Storm-Mathisen I, Hirschberg H: Survival, prognostic factors and therapeutic efficacy in low-grade glioma: A retrospective study in 379 patients. J Clin Oncol 15:3129-3140, 1997.
78. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 7:1277-1280, 1990.
79. Macdonald DR, Gaspar LE, Cairncross JG: Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27:573-574, 1990.
80. Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 46:203-207, 1996.
81. Medbery CA, Straus KL, Steinberg SM, Cotelingam JD, Fisher WS: Low-grade astrocytomas: Treatment results and prognostic variables. Int J Radiat Oncol Biol Phys 15:837-841, 1988.
82. Melmed S: Reply to Dowsett and Fowble on radiotherapy for acromegaly. N Engl J Med 323:612-613, 1990 (letter).
83. Mørk SJ, Halvorsen TB, Lindegaard K-F, Eide GE: Oligodendroglioma: Histologic evaluation and prognosis. J Neuropathol Exp Neurol 45:65-78, 1986.
84. Mulherk RK, Kun LE: Changes in intellect associated with cranial radiation therapy, in Gutin PH, Sheline GE (eds): Radiation Injury to the Nervous System. New York, Raven, 1991, pp 325-340.
85. Nazzaro JM, Neuwelt EA: The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg 73:331-344, 1990.
86. Nicolato A, Gerosa MA, Fina P, Iuzzolino P, Giorgiutti F, Bricolo A: Prognostic factors in low-grade supratentorial astrocytomas: A uni-multivariate statistical analysis in 76 surgically treated adult patients. Surg Neurol 44:208-223, 1995.
87. Nijjar TS, Simpson WJ, Gadalla T, McCartney M: Oligodendroglioma: The Princess Margaret Hospital experience (1958-1984). Cancer 71:4002-4006, 1993.
88. North CA, North RB, Epstein JA, Piantadosi S, Wharam MD: Low-grade cerebral astrocytomas: Survival and quality of life after radiation therapy. Cancer 66:6-14, 1990.
89. Paulus W, Peiffer J: Intratumoral histologic heterogeneity of gliomas: A quantitative study. Cancer 64:442-447, 1989.
90. Peterson K, Cairncross JG: Oligodendrogliomas. Neurol Clin 13:861-873, 1995.
91. Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG: Salvage chemotherapy for oligodendroglioma. J Neurosurg 85:597-601, 1996.
92. Piepmeier J, Christopher S, Spencer D, Byrne T, Kim J, Knisel JP, Lacy J, Tsukerman L, Makuch R: Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 38:872-879, 1996.
93. Raff MC, Williams BP, Miller RH: The in vitro differentiation of a bipotential glial progenitor cell. EMBO J 8:1857-1864, 1984.
94. Remsen LG, McCormick CI, Sexton G, Pearse HD, Garcia R, Mass M, Roman-Goldstein S, Neuwelt EA: Long-term toxicity and neuropathology associated with the sequencing of cranial irradiation and enhanced chemotherapy delivery. Neurosurgery 40:1034-1042, 1997.
95. Roberts M, German WJ: A long term study of patients with oligodendrogliomas: Follow-up of 50 cases, including Dr. Harvey Cushing's series. J Neurosurg 24:697-700, 1966.
96. Roessler K, Nasel C, Czech T, Matula CH, Lassmann H, Koos WT: Histological heterogeneity of neuroradiologically suspected adult low grade gliomas detected by xenon enhanced computerized tomography (CT). Acta Neurochir (Wien) 138:1341-1347, 1996.
97. Rostomily RC, Keles GE, Berger MS: Radical surgery in the management of low-grade and high-grade gliomas. Baillieres Clin Neurol 5:345-369, 1996.
98. Russell DS, Rubinstein LJ: Pathology of Tumours of the Nervous System. Baltimore, Williams & Wilkins, 1971, pp 147-153.
99. Rutka JT, Murakami M, Dirks PB, Hubbard SL, Becker LE, Fukuyama K, Jung S, Tsugu A, Matsuzawa K: Role of glial filaments in cells and tumors of glial origin: A review. J Neurosurg 87:420-430, 1997.
100. Saarinen UM, Pihko H, Mäkipernaa A: High-dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma: A case report. J Neurooncol 9:57-61, 1990.
101. Salcman M: Resection and reoperation in neuro-oncology: Rationale and approach. Neurol Clin 3:831-842, 1985.
102. Scerrati M, Roselli R, Lacoangeli M, Pompucci A, Rossi GF: Prognostic factors in low grade (WHO grade II) gliomas of the cerebral hemispheres: The role of surgery. J Neurol Neurosurg Psychiatry 61:291-296, 1996.
103. Seiler RW: Late results of multimodality therapy of high-grade supratentorial astrocytomas. Surg Neurol 15:88-91, 1981.
104. Shapiro WR, Young DF: Treatment of malignant glioma: A controlled study of chemotherapy and irradiation. Arch Neurol 33:494-500, 1976.
105. Shaw EG: The low-grade glioma debate: Evidence defending the position of early radiation therapy. Clin Neurosurg 42:488-494, 1995.
106. Shaw EG, Scheithauer BW, O'Fallon JR: Supratentorial gliomas: A comparative study by grade and histologic type. J Neurooncol 31:273-278, 1997.
107. Shaw EG, Scheithauer BW, O'Fallon JR, Davis DH: Mixed oligoastrocytomas: A survival and prognostic factor analysis. Neurosurgery 34:577-582, 1994.
108. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH: Oligodendrogliomas: The Mayo Clinic experience. J Neurosurg 76:428-434, 1992.
109. Sheline G, Wara WM, Smith V: Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 6:1215-1228, 1980.
110. Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashley SE, Brada M: Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys 37:393-398, 1997.
111. Shimizu KT, Tran LM, Mark RJ, Selch MT: Management of oligodendrogliomas. Radiology 186:569-572, 1993.
112. Smith MT, Ludwig CL, Godfrey AD, Armbrustmatcher VW: Grading of oligodendrogliomas. Cancer 52:2107-2114, 1983.
113. Taphoorn MJ, Heimans JJ, Snoek FJ, Lindeboom J, Oosterink B, Wolbergs JG, Karim AB: Assessment of quality of life in patients treated for low-grade glioma: A preliminary report. J Neurol Neurosurg Psychiatry 55:372-376, 1992.
114. Tice H, Barnes PD, Goumnerova L, Scott RM, Tarbell NJ: Pediatrie and adolescent oligodendrogliomas. AJNR Am J Neuroradiol 14:1293-1300, 1993.
115. Ushio Y, Hayakawa H: Chemotherapy of malignant gliomas. Neurosurg Rev 7:3-12, 1984.
116. Vigliani MC, Sichez N, Poisson M, Delattre JY: A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int J Radiat Oncol Biol Phys 35:527-533, 1996.
117. Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ranshoff J, Wilson CB, Gehan EA, Shike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49:333-344, 1978.
118. Westergaard L, Gjerris F, Klinken L: Prognostic parameters in benign astrocytomas. Acta Neurochir (Wien) 123:1-7, 1993.
119. Wolswijk G, Noble M: Identification of an adult-specific glial progenitor cell. Development 105:387-400, 1989.
120. Wren DR, Wolswijk G, Noble M: In vitro analysis of the origin and maintenance of O-2A adult progenitor cells. J Cell Biol 116:167-176, 1992.